Skip to Content
Merck
All Photos(2)

Documents

CIX001

Sigma-Aldrich

ComInnex IAP Ligand Library

Sign Into View Organizational & Contract Pricing
All Photos(2)

About This Item

UNSPSC Code:
41116105
NACRES:
NA.22

form

solid (powder or film on well wall)

Quality Level

200

reaction suitability

reagent type: ligand

concentration

125 μg/well

suitability

suitable for H-NMR
suitable for LC-MS

storage temp.

2-8°C

Related Categories

Application

The ComInnex IAP Ligand Library is an 80-member collection of in-silico-derived ligands targeting cellular inhibitor of apoptosis protein 1 (cIAP1). cIAP1 is an E3 ligase of interest for the development of protein degraders, specifically called specific and non-genetic IAP-dependent protein erasers (SNIPERs).

Based on the SAR rules outlined in IAP antagonist research, the binding tetrapeptide anchor of the natural SMAC inhibitor protein of IAPs (AVPI and AVPF) was used in identification of novel derivatives designed by 3D similarity.

The initial library was filtered via in silico IFD methods by docking to the BIR3 domain of the IAP crystal structures. The highest binding derivatives were selected and collected in a screening library, including the natural binding tetrapeptides and known MV1 reference compounds. IAP in silico leads are an optimal collection to begin IAP lead discovery at the bench for eventual development into bifunctional protein degraders. With the proper assay setup to measure protein degradation or protein-protein interactions (PPIs), the ComInnex IAP Ligand Library can also be a platform for molecular glue discovery.

Learn more about this library: Accelerating IAP Lead Discovery for Targeted Protein Degradation

To view a complete list of compounds in the library, including sdf, visit the CIX001 Plate Map.

To streamline the assessment of these in silico leads for target-specific bifunctional degraders, three IAP ligands with the highest docking scores were also prepared as degrader building blocks for simple attachment of a target warhead.

Biochem/physiol Actions

80 compounds are arranged in 96-microtube format with two open rows for screening controls if using liquid handling setups. One compound per tube (125 μg in solid form). Compound concentration in assays will vary depending on assay type, but common screening library stock solutions are 2 mM or 10 mM in DMSO.

Other Notes

Inhibitor of Apoptosis Protein (IAP) Antagonists in Anticancer Agent Discovery: Current Status and Perspectives

Degrader Building Blocks (including CRBN- and VHL-targeting ligands)

related product

Product No.
Description
Pricing

917931

A1V2PF2-NHEt-C6-NH2

916684

A1V2PF2-NHEt-C10-NH2, ≥95%

917680

BocA1V1PF2-OPEG3-NH2 hydrochloride

917966

BocA1V2PF1-NHC6-NH2

917702

A1V2PF1-NHEt-PEG3-NH2

917451

A1V2PF1-NHEt-PEG1-NH2, ≥95%

917974

BocA1V2PF2

917710

A1V1PF2-OEt, ≥95%

917478

BocA1V1PF2, ≥95%

917214

BocA1V2PF1-NHPEG3-NH2, ≥85%

916951

BocA1V2PF1-NHPEG1-NH2

916927

BocA1V1PF2-OC6-NH2 hydrochloride, ≥95%

916676

A1V1PF2-OEt-PEG3-NH2 hydrochloride

917923

A1V1PF2-OEt-PEG1-NH2 hydrochloride

917672

A1V1PF2-OEt-C10-NH2 hydrochloride

917206

A1V2PF1-NHEt-C10-NH2

917184

BocA1V1PF2-OC10-NH2 hydrochloride

916943

A1V2PF1-NHEt-C6-NH2

916692

BocA1V2PF2-NHPEG3-NH2, ≥95%

917427

A1V1PF2-OEt-C6-NH2 hydrochloride

916706

BocA1V2PF1-NHC10-NH2

917435

BocA1V1PF2-OPEG1-NH2 hydrochloride, ≥95%

916978

BocA1V2PF1, ≥95%

917699

BocA1V2PF2-NHC10-NH2, ≥85%

917222

A1V2PF1-NHEt, ≥95%

917958

BocA1V2PF2-NHPEG1-NH2

916714

A1V2PF2-NHEt, ≥95%

917192

A1V2PF2-NHEt-PEG3-NH2, ≥95%

916935

A1V2PF2-NHEt-PEG1-NH2

917443

BocA1V2PF2-NHC6-NH2

Storage Class Code

11 - Combustible Solids

WGK

WGK 3

Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Norihito Shibata et al.
Cancer science, 108(8), 1657-1666 (2017-05-31)
Chromosomal translocation occurs in some cancer cells, which results in the expression of aberrant oncogenic fusion proteins that include BCR-ABL in chronic myelogenous leukemia (CML). Inhibitors of ABL tyrosine kinase, such as imatinib and dasatinib, exhibit remarkable therapeutic effects, although
Keiichiro Okuhira et al.
Molecular pharmacology, 91(3), 159-166 (2016-12-15)
Development of novel small molecules that selectively degrade pathogenic proteins would provide an important advance in targeted therapy. Recently, we have devised a series of hybrid small molecules named SNIPER (specific and nongenetic IAP-dependent protein ERaser) that induces the degradation
Yukihiro Itoh et al.
Bioorganic & medicinal chemistry letters, 22(13), 4453-4457 (2012-06-05)
Protein knockdown can be achieved by the use of a small molecule that possesses affinity for both the target protein and ubiquitin ligase. We have designed such a degradation-inducing molecule targeting cIAP1 and CRABP-II, which are involved in proliferation of
Nobumichi Ohoka et al.
The Journal of biological chemistry, 292(11), 4556-4570 (2017-02-06)
Many diseases, especially cancers, result from aberrant or overexpression of pathogenic proteins. Specific inhibitors against these proteins have shown remarkable therapeutic effects, but these are limited mainly to enzymes. An alternative approach that may have utility in drug development relies
Mikihiko Naito et al.
Drug discovery today. Technologies, 31, 35-42 (2019-06-16)
The induction of protein degradation by chimeric small molecules represented by proteolysis-targeting chimeras (PROTACs) is an emerging approach for novel drug development. We have developed a series of chimeric molecules termed specific and non-genetic inhibitor of apoptosis protein (IAP)-dependent protein

Articles

Accelerating Protein Degrader Discovery with IAP

Plate of 80 ligands against E3 ligase IAP designed by ComInnex; allows creation of bifunctional targeted protein degraders or molecular glues.

Accelerating Protein Degrader Discovery with IAP

Plate of 80 ligands against E3 ligase IAP designed by ComInnex; allows creation of bifunctional targeted protein degraders or molecular glues.

Accelerating Protein Degrader Discovery with IAP

Plate of 80 ligands against E3 ligase IAP designed by ComInnex; allows creation of bifunctional targeted protein degraders or molecular glues.

Accelerating Protein Degrader Discovery with IAP

Plate of 80 ligands against E3 ligase IAP designed by ComInnex; allows creation of bifunctional targeted protein degraders or molecular glues.

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service